1234780-32-5

Basic information

• Product Name: N³-(4-bromobenzyl)cyanonilutamide
• Synonyms: N³-(4-bromobenzyl)cyanonilutamide
• CAS NO: 1234780-32-5
• Molecular Weight: 466.257
• Mol File: 1234780-32-5.mol

Chemical Properties

• CAS DataBase Reference: N³-(4-bromobenzyl)cyanonilutamide(CAS DataBase Reference)
• NIST Chemistry Reference: N³-(4-bromobenzyl)cyanonilutamide(1234780-32-5)
• EPA Substance Registry System: N³-(4-bromobenzyl)cyanonilutamide(1234780-32-5)

Safety Data

• Hazardous Substances Data: 1234780-32-5(Hazardous Substances Data)

Upstream product

• 589-15-1 1-bromomethyl-4-bromobenzene 
• 143782-20-1 4-(4,4-dimethyl-2,5-dioxoimidazolidin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 143782-19-8 4-(4,4-Dimethyl-5-imino-2-oxo-1-imidazolidinyl)-2-trifluoromethyl-benzonitrile 
• 143782-18-7 4-isocyanato-2-(trifluoromethyl)benzonitrile 
• 654-70-6 4-amino-2-trifluoromethylbenzonitrile 

Relevant articles and documents

HYDANTOIN-DERIVED HISTONE DEACETYLASE (HDAC) INHIBITORS AND METHODS OF MAKING AND USING THEREOF

The disclosure is directed to compounds and methods of using compounds of Formula II. The compounds and methods are effective as inhibitors of to hydantoin-derived histone deacetylase (HDAC), such as in proliferative disease states. The compounds can be f

NON-STEROIDAL ANTIANDROGENS AND SELECTIVE ANDROGEN RECEPTOR MODULATORS WITH A PYRIDYL MOIETY

Compounds having the structure or their salts: are used to treat or reduce the likelihood of acquiring androgen-dependent diseases, such as prostate cancer, benign prostatic hyperplasia, polycystic ovarian syndrome, acne, hirsutism, seborrhea, androgenic alopecia, male baldness, muscle atrophy and weakness, sarcopenia, male hypogonadism, erectile dysfunction, female sexual dysfunction and osteoporosis. They can be formulated together with pharmaceutically acceptable diluent or carrier or otherwise made into any pharmaceutical dosage form. Combinations with other active pharmaceutical agents are also disclosed.

Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, process for preparing them, medicaments comprising these compounds, and their use

This invention relates to arylaminoaryl-alkyl-substituted imidazolidone-2,4-diones of formula (I) and also to their physiologically tolerated salts: Wherein R, R′, R1 to R10, A, D, E, G, L and p are as defined herein. The invention also relates to processes for preparing them, pharmaceutical compositions comprising them and their therapeutic use. The compounds are suitable, for example, as anti-obesity drugs and for treating cardiometabolic syndrome.